BTIG Maintains Buy on BrightSpring Health, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst David Larsen maintains a Buy rating on BrightSpring Health (NASDAQ:BTSG) and raises the price target from $15 to $20.
October 03, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst David Larsen has reaffirmed a Buy rating for BrightSpring Health and increased the price target from $15 to $20, indicating a positive outlook.
The reaffirmation of a Buy rating and an increased price target from a reputable analyst can boost investor confidence, likely leading to a positive short-term impact on BTSG's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100